Skip to main content
Tesamorelin Research

Stanley 2019 — Tesamorelin NAFLD Study

Lancet HIV

Stanley TL, et al.

Summary

Liver fat reduction in HIV

Study Details
Study Design

Phase 3 RCT

Indication

NAFLD in HIV

Intervention

Tesamorelin 2 mg SC daily

Species

Human

Tags
SourceRCTPhase3TesamorelinNAFLDHIVLancet
Metrics
Citations
0
Evidence QualityN/A
Related PeptideTesamorelin6 papers